Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2021 | Genomic landscape of Waldenström’s

Jorge Castillo • 16 Apr 2021
COMy 2021
Lymphoma Rare Diseases Waldenström’s Macroglobulinemia Antibodies EPI-X 4 Ulocuplumab

Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, talks on the genomic landscape of Waldenström’s macroglobulinemia and how it impacts treatment strategies. A variety of targets are discussed. Specifically highlighted is the MYD88 mutation, which Dr Castillo considers one of the biggest advancements in Waldenström’s in 75 years. Finally, novel agents for WM are discussed. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.

Disclosures

Jorge Castillo receives research funds and/or honoraria from Abbvie, Beigene, Janssen, Pharmacyclics, Roche, TG Therapeutics

More from Jorge Castillo

2:22
Real-world outcomes following dose reduction of first-line ibrutinib in patients with WM
Jorge Castillo • 10 Dec 2023
2:27
Acalabrutinib plus rituximab for treating anti-MAG mediated IgM peripheral neuropathy in WM
Jorge Castillo • 10 Dec 2023
3:03
Outcomes following venetoclax monotherapy in patients with R/R WM in the real-world setting
Jorge Castillo • 10 Dec 2023
3:32
Research updates in WM from ASH 2023
Jorge Castillo • 10 Dec 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals